Publikationen, an denen er mitarbeitet Ignacio Gil Bazo (21)

2023

  1. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

    Journal of Translational Medicine, Vol. 21, Núm. 1

2022

  1. MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

    European Journal of Cancer, Vol. 174, pp. S122

2021

  1. Delta-radiomics signature for prediction of survival in advanced nsclc patients treated with immunotherapy

    Proceedings - International Symposium on Biomedical Imaging

2018

  1. Guía inmunotoxicidad: diagnóstico y manejo de los efectos secundarios asociados a inmunoterapia en oncología

    EUNSA. Ediciones Universidad de Navarra, S.A.

2017

  1. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche

    Cancer Letters, Vol. 402, pp. 43-51

2016

  1. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes

    Brachytherapy, Vol. 15, Núm. 2, pp. 127-135

  2. Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients

    Clinical and Translational Oncology, Vol. 18, Núm. 3, pp. 259-268

2015

  1. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis

    Journal of Translational Medicine, Vol. 13, Núm. 1

  2. Looking into the "Garden of the Hesperides": New drugs for hepatocellular carcinoma

    Minerva Chirurgica, Vol. 70, Núm. 2, pp. 119-129

  3. Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors

    Minerva Chirurgica

  4. cMET in NSCLC: Can we cut off the head of the Hydra? From the pathway to the resistance

    Cancers, Vol. 7, Núm. 2, pp. 556-573

2014

  1. Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications

    Clinical Genitourinary Cancer, Vol. 12, Núm. 2, pp. 87-93

  2. Epidermal growth factor receptor targeting in non-small cell lung cancer: Revisiting different strategies against the same target

    Current Drug Targets, Vol. 15, Núm. 14, pp. 1273-1283

  3. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed

    Journal of Translational Medicine, Vol. 12, Núm. 1

2013

  1. Clinical management of small-cell carcinoma of the urinary tract: A 10-year single-center's experience

    Clinical Genitourinary Cancer, Vol. 11, Núm. 2, pp. 168-174

  2. Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy

    Journal of Translational Medicine, Vol. 11, Núm. 1

  3. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: A retrospective cohort study

    Journal of Neuro-Oncology

  4. Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer

    Clinical Genitourinary Cancer, Vol. 11, Núm. 2, pp. 78-84

2012

  1. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: Preliminary data on clinical outcome

    International Journal of Radiation Oncology Biology Physics, Vol. 82, Núm. 3

2011

  1. EGFR mutation testing in nonsmall cell lung cancer patients by using cytology specimens: When the tissue is no longer the issue

    Cancer Cytopathology